YOLFTbeta
Quest PharmaTech Inc

Quest PharmaTech Inc

QPT · V · Healthcare / Biotechnology

0.02CAD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.02
Open0.02
Day Range0.02 – 0.02
52-Week Range0.02 – 0.05
Volume90.00K
Market Cap4.23M
P/E (TTM)0.83
Forward P/E0.00
EPS0.03
Dividend Yield0.00%
Beta-0.31
50-Day Avg0.024
200-Day Avg0.0321

About

Quest PharmaTech Inc., a pharmaceutical company, develops targeted cancer therapies in Canada. Its lead product is MAb AR9.6, a theranostic agent for cancer in preclinical development for pancreatic cancer. The company is headquartered in Edmonton, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Ragupathy Madiyalakan Ph.D.
  • Employees0
  • Headquarters97 Street NW, Edmonton, AB, Canada, T6E 5R9, Canada
  • Websitehttps://www.questpharmatech.com

Leadership

  • Dr. Ragupathy Madiyalakan Ph.D.CEO & Director
  • Mr. Pierre Vermette C.A., CPAChief Financial Officer
  • Mr. Roger AndrewsHead of Investor Relations & Corporate Communications
  • Mr. Douglas C. BachmanVice President of Corporate Development · b. 1954
  • Mr. Thomas WooVice President of Product Development

Financials

Income Statement

Currency: CAD1998-01-312014-01-312015-01-312016-01-312017-01-312018-01-312019-01-312020-01-312021-01-312022-01-312023-01-312024-01-312025-01-312026-01-31
Total Revenue4.32K0002.57K38.87K00000000
Growth (%)--100.00%---+1413.08%-100.00%-------
Cost of Revenue00001.19K17.73K--------
Gross Profit4.32K0001.38K21.14K--------
Gross Margin100.00%---53.80%54.39%--------
Operating Expense84.39K2.09M2.66M2.21M4.32M7.82M--------
Operating Income-80.07K-2.09M-2.66M-2.21M-4.32M-7.79M-9.04M-13.63M-1.07M-790.57K-834.22K-1.32M-817.28K-711.26K
Operating Margin-1852.61%----168036.55%-20050.62%--------
EBITDA------9.10M-8.63M-13.20M190.11M-84.99M-7.30M-2.99M-1.78M5.02M
EBITDA Margin------23399.76%--------
Net Income-80.07K-272.33K-1.82M-4.63M-4.13M-5.09M-4.39M-6.18M190.06M-85.04M-7.33M-3.02M-1.80M5.00M
Net Income Margin-1852.61%----160934.92%-13084.82%--------
R&D-1.30M1.65M1.20M2.10M5.51M6.27M11.26M212.50K170.24K336.23K542.86K329.18K242.32K
R&D as % of Total Revenue----81817.01%14166.07%--------
Interest Expense0000004.42K13.74K7.77K13.06K21.00K20.68K22.64K20.33K
Interest Expense % of Total Revenue0.00%---0.00%0.00%--------

Balance Sheet

Currency: CAD1998-01-312014-01-312015-01-312016-01-312017-01-312018-01-312019-01-312020-01-312021-01-312022-01-312023-01-312024-01-312025-01-312026-01-31
Total Assets326.25K901.85K331.99K10.87M11.37M12.78M5.81M4.45M175.61M91.03M84.36M24.48M22.56M27.75M
Total Liabilities3.47K3.31M4.07M13.30M733.49K9.95M10.14M20.95M389.44K622.60K1.11M1.32M1.17M1.33M
Total Equity322.79K-2.41M-3.73M-2.32M11.02M-7.38M-10.27M-15.34M175.22M90.41M83.25M23.15M21.40M26.43M
Cash321.09K742.45K100.04K788.63K1.22M416.44K347.30K2.15M199.11K264.34K374.66K716.96K205.09K14.36K
Net Debt-------493.42K50.89K235.66K625.34K283.04K794.91K985.64K

Cash Flow

Currency: CAD1998-01-312014-01-312015-01-312016-01-312017-01-312018-01-312019-01-312020-01-312021-01-312022-01-312023-01-312024-01-312025-01-312026-01-31
Operating Cash Flow-81.77K-1.96M-1.94M-2.56M-4.61M-7.33M-6.91M-6.38M-2.52M-170.78K-554.68K-342.42K-511.88K-190.72K
Investing Cash Flow--4.72K-9.20K-525.38K-24.85K-2.98M8.26M2.78M261.96K-14.00K-14.00K---
Financing Cash Flow259.86K2.65M1.31M3.79M5.11M9.46M-1.42M5.40M299.00K250.00K679.00K684.72K0-
Capital Expenditure04.72K9.20K1.13K8.94K8.72K1.63K35.85K38.04K00000
Free Cash Flow------7.33M-6.91M-6.38M-2.55M-170.78K-554.68K-342.42K-511.88K-190.72K
FCF to OCF-----100.12%100.02%100.00%101.51%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateApr 30, 2007Jul 31, 2007Oct 31, 2007Jan 31, 2008Apr 30, 2008Jul 31, 2008Oct 31, 2008Jan 31, 2009Apr 30, 2009Jul 31, 2009Oct 31, 2009Jan 31, 2010Apr 30, 2010Jul 31, 2010Oct 31, 2010Jan 31, 2011Apr 30, 2011Jul 31, 2011Oct 31, 2011Jan 31, 2012Apr 30, 2012Jul 31, 2012Oct 31, 2012Jan 31, 2013Apr 30, 2013Jul 31, 2013Oct 31, 2013Jan 31, 2014Apr 30, 2014Jul 31, 2014Oct 31, 2014Jan 31, 2015Apr 30, 2015Jul 31, 2015Oct 31, 2015Jan 31, 2016Apr 30, 2016Jul 31, 2016Oct 31, 2016Jan 31, 2017Apr 30, 2017Jul 31, 2017Oct 31, 2017Jan 31, 2018Apr 30, 2018Jul 31, 2018Oct 31, 2018Jan 31, 2019Apr 30, 2019Jul 31, 2019Oct 31, 2019Jan 31, 2020Apr 30, 2020Jul 31, 2020Oct 31, 2020Jan 31, 2021Apr 30, 2021Jul 31, 2021Oct 31, 2021Jan 31, 2022Apr 30, 2022Sep 26, 2022Oct 31, 2022Jan 31, 2023Jun 29, 2023Sep 27, 2026May 31, 2027
EPS Estimate-------------------------------------------------------------------
EPS Actual-0.00-0.01-0.01-0.000.00-0.00-0.00-0.000.000.00-0.00-0.01-0.00-0.01-0.00-0.01-0.00-0.00-0.00-0.01-0.00-0.01-0.01-0.01-0.00-0.01-0.010.01-0.00-0.00-0.00-0.01-0.00-0.00-0.00-0.03-0.00-0.01-0.01-0.01-0.01-0.01-0.010.00-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.010.630.020.020.46-0.000.00-0.05-0.45-0.01-0.00-0.01-0.03-0.03--
Surprise-------------------------------------------------------------------
Timing-------------------------------------------------------------After-hours--After-hoursPre-marketAfter-hours

Key Statistics & Ratios

Market Cap4.23M
Enterprise Value5.21M
Trailing P/E0.83
Forward P/E0.00
PEG Ratio0.00
Price / Sales515.97
Price / Book0.16
EPS0.03
Book Value0.158
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-814.31K
Profit Margin0.00%
Operating Margin0.00%
Return on Equity19.96%
Return on Assets-1.66%
Shares Outstanding169.13M
Shares Float138.75M
Beta-0.31
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20053×
0.06Jul 21, 20050.06Apr 21, 20050.06Jan 21, 2005
20044×
0.06Oct 21, 20040.06Jul 22, 20040.06May 3, 20040.06Jan 22, 2004
20034×
0.06Oct 23, 20030.06Jul 23, 20030.06Apr 23, 20030.06Jan 23, 2003
20024×
0.06Oct 23, 20020.06Jul 23, 20020.06Apr 23, 20020.06Jan 23, 2002
20014×
0.06Oct 29, 20010.06Jul 23, 20010.06Apr 23, 20010.06Jan 23, 2001
20004×
0.06Oct 23, 20000.06Jul 21, 20000.06Apr 20, 20000.06Jan 21, 2000
19991×
0.06Oct 21, 1999